Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API

IBRX
ImmunityBio, Inc. Common Stock
stock NASDAQ

Market Open
Aug 11, 2026 3:21:19 PM EDT
7.61USD+1.400%(+0.11)3,675,596
7.60Bid   7.61Ask   0.01Spread
Pre-market
Aug 11, 2026 9:27:30 AM EDT
7.57USD+0.933%(+0.07)22,627
After-hours
Aug 10, 2026 4:41:30 PM EDT
7.51USD+0.133%(+0.01)0
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 31, 2022
08:11PM EST  ImmunityBio Inc. (IBRX) announced promising phase 1 study results that demonstrated the activation of CD4+ and CD8+ T cells and natural killer cells in people living with HIV by the company's IL-15 superagonist Anktiva (N-803). The study results were published in Nature Medicine.   RTTNews
07:16PM EST  ImmunityBio Announces Promising Clinical Study Results for 'Kick and Kill' HIV Cure Strategy to Reduce HIV Viral Load with Anktiva (N-803) Therapy   Business Wire
Jan 25, 2022
06:14AM EST  ImmunityBio Granted U.S. Patent #11,230,699 'Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors'   Benzinga
Jan 20, 2022
07:55AM EST  Immunity Bio Filed U.S. Patent Application #20220016234 'ANTI COVID-19 THERAPIES USING NUCLEOCAPSID AND SPIKE PROTEIN'   Benzinga
Jan 19, 2022
07:40AM EST  The Daily Biotech Pulse: Gamida Gains On Positive Regulatory Development, Orphazyme & ADMA Preannouncements, ImmunityBio & Leap Present Positive Data   Benzinga
Jan 18, 2022
06:04PM EST  ImmunityBio Announces Results Of Phase 2 Metastatic Pancreatic Cancer Trial At ASCO GI With Median Overall Survival Of 6.3 Months In Patients With Third-Line Disease, More Than Doubling Historical Survival   Benzinga
Jan 16, 2022
04:38PM EST  The Week Ahead In Biotech (Jan 16-22): Focus On Data Presentations And IPOs In Holiday-Shortened Week   Benzinga
Jan 12, 2022
08:32AM EST  Athenex Reports Deal For ImmunityBio To Assume Leasehold Interest In Manufacturing Facility In Dunkirk, New York, Certain Related Assets For ~$38M   Benzinga
08:30AM EST  Athenex Announces Agreement with ImmunityBio Regarding Dunkirk   GlobeNewswire Inc
Jan 3, 2022
08:17AM EST  Amyris, ImmunityBio Complete JV Agreement To Accelerate Commercialization Of COVID-19 Vaccine   RTTNews
08:03AM EST  Amyris and ImmunityBio Execute a Joint Venture Agreement to Commercialize a COVID-19 Vaccine   Benzinga
08:01AM EST  AMYRIS AND IMMUNITYBIO COMPLETE JOINT VENTURE FOR NEXT GENERATION COVID-19 RNA   PR Newswire
Dec 28, 2021
06:13AM EST  ImmunityBio Granted U.S. Patent #11,207,350 'Genetically modified NK-92 cells and monoclonal antibodies for the treatment of cancer'   Benzinga
Dec 20, 2021
09:16AM EST  ImmunityBio Announces Completion Of $470M Post-Merger Financing   Benzinga
Dec 15, 2021
08:54AM EST  Benzinga Pro's Top 5 Stocks To Watch For Wednesday, Dec. 15, 2021: RBLX, IBRX, AHPI, HLBZ, TEKK   Benzinga
Nov 18, 2021
09:05AM EST  ImmunityBio Expands Vaccine Program To Accelerate Use Of 'Mix-And-Match' Technologies In Developing And Manufacturing Next-Generation COVID-19 Vaccines   Benzinga
Nov 8, 2021
10:15AM EST  Amyris, ImmunityBio Join Forces For Next-Gen COVID-19 RNA Vaccine   Benzinga
08:08AM EST  Amyris Partners With ImmunityBio For Next Generation COVID-19 RNA Vaccine   RTTNews
08:07AM EST  Amyris Announces JV Partnership With ImmunityBio For Next Generation COVID-19 RNA Vaccine   Benzinga
08:03AM EST  Amyris Announces JV Partnership With ImmunityBio For Next Generation COVID-19   PR Newswire
Oct 19, 2021
03:49PM EDT  ImmunityBio Meets Endpoint In Second Indication Cohort In Bladder Cancer Trial   Benzinga
09:10AM EDT  ImmunityBio Says Co Meets Primary Endpoint In Second Indication In Bladder Cancer Trial With 57% Disease-Free Survival In Patients With BCG Unresponsive Papillary Disease   Benzinga
Oct 13, 2021
01:38PM EDT  ImmunityBio Completes Enrollment In Phase 2 Study Of Nant Cancer Vaccine For 3rd Line Or Greater Metastatic Pancreatic Cancer Patients; Says 90% of Patients Have Exceeded Historical Survival Rates To Date   Benzinga
Oct 4, 2021
08:37AM EDT  ImmunityBio Reports Lung-MAP Public-Private Partnership With Study Co.'s IL-15 Receptor Superagonist Complex In Trial   Benzinga
Sep 13, 2021
08:38AM EDT  ImmunityBio Announces Updated Data From Ongoing Bladder Cancer Trial Showing Complete Response Rate Of 72%   Benzinga
Sep 10, 2021
08:00AM EDT  The Daily Biotech Pulse: Apellis Sinks On Data, Endo Shines On Opioid Litigation Settlement, T2 Biosystems Soars On Mutant Detection Ability of COVID Test   Benzinga
Sep 8, 2021
07:43AM EDT  Johnson & Johnson Plans COVID-19 Booster Shot Trial In South Africa: Bloomberg   Benzinga
Sep 5, 2021
01:14PM EDT  The Week Ahead In Biotech (Sept. 5-11): Focus On Conferences and Clinical Readouts In Another Quiet Week   Benzinga
Sep 1, 2021
09:01AM EDT  ImmunityBio Announces Oral Presentation Of Phase 2/3 Clinical Trial Results Of Patients With BCG-Unresponsive Bladder Cancer Carcinoma At Upcoming American Urological Association's Annual Meeting   Benzinga
Aug 16, 2021
11:33AM EDT  ImmunityBio Sponsored Study Atezolizumab And N-803 After Progression On Any Immune Checkpoint Blocker In NSCLC Posted To Clinical Trials Website Not Yet Recruiting   Benzinga
Jul 27, 2021
11:13AM EDT  ImmunityBio Granted US Patent For NANT Cancer Vaccine   Benzinga
Jul 14, 2021
09:05AM EDT  ImmunityBio Announces South African Authorization To Proceed With Phase 1/2/3 Randomized Trial In South AfricaOf Their Dual-Antigen T-Cell Vaccine As A Universal Boost In Previously Vaccinated Participants Against COVID-19   Benzinga
Jul 8, 2021
08:08AM EDT  Cramer Weighs In On Cloudflare, MP Materials And More   Benzinga
Jun 28, 2021
09:05AM EDT  ImmunityBio Highlights Publication In Journal for Immunotherapy of Cance   Benzinga
Jun 24, 2021
09:34AM EDT  ImmunityBio Files For U.S. Patent Titled 'NK-92 Cells to Stimulate Anti-Cancer Vaccine'   Benzinga
Jun 23, 2021
04:05PM EDT  Motus GI Appoints Experienced Financial Biotech Executive, Sonja   GlobeNewswire Inc
Jun 16, 2021
02:09PM EDT  ImmunityBio ClinicalTrials.gov Study Record Detail For Co.'s 'A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior Therapies,' Shows Not Yet Recruiting   Benzinga
Jun 15, 2021
07:05AM EDT  FDA Authorizes ImmunityBio's Study Of Anktiva And PD-L1 t-haNK To Increase Effectiveness Of Trodelvy In Triple-Negative Breast Cancer   Benzinga
Jun 10, 2021
09:37AM EDT  ImmunityBio Announces HIV Clinical Pipeline With Opening Of A Phase 1 'HIV Cure Study' In Patients Off Therapy   RTTNews
09:00AM EDT  ImmunityBio Announces HIV Clinical Pipeline with Opening of a Phase 1 'HIV Cure Study' in Patients Off Therapy and a Phase 2 Study in Acutely Infected Patients   Business Wire
May 25, 2021
09:09AM EDT  ImmunityBio Announces Two South African Sttudies To 'examine the potential for using its hAd5 T-cell-based COVID-19 vaccine candidate to provide extended protection for subjects with prior COVID-19 vaccinations or infections'   Benzinga
May 24, 2021
10:45AM EDT  ImmunityBio Publishes Study To ClinicalTrials.Gov Titled 'QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors'   Benzinga
09:10AM EDT  ImmunityBio To Present At Jefferies 2021 Virtual Healthcare Conference Jun. 4   Benzinga
May 20, 2021
09:05AM EDT  ImmunityBio To Present Preliminary Phase 2 Anktiva Data At ASCO 2021   Benzinga
09:00AM EDT  ImmunityBio to Present Preliminary Phase 2 Data of 68% Durable Disease Control with Anktiva Plus Checkpoint Inhibitor in First 140 Patients Enrolled with Lung Cancer and Multiple Tumor Types Who Failed Prior Checkpoint Therapy at ASCO 2021   Business Wire
May 17, 2021
12:32PM EDT  ImmunityBio Shares Jump As It Plans To Start Testing Memory Cytokine-Enriched NK Cell Platform In Solid Tumors Patients   Benzinga
10:27AM EDT  ImmunityBio Says FDA Authorizes Co To Conduct Trial Of Its First-In-Human, Cryopreserved, Memory Cytokine-Enriched NK Cell Platform In Solid Tumors   Benzinga
09:36AM EDT  ImmunityBio, Inc. (IBRX) Monday said has received FDA authorization to conduct a Phase 1 human study of its Memory Cytokine-Enriched NK cell platform combined with its IL-15 superagonist Anktiva in subjects with locally advanced or metastatic solid tumors.   RTTNews
09:09AM EDT  ImmunityBio Gets FDA Authorization To Conduct Trial Of First-in-Human, Cryopreserved, M-ceNK Platform In Solid Tumors   RTTNews
09:00AM EDT  FDA Authorizes ImmunityBio to Conduct a Trial of its First-in-Human, Cryopreserved, Memory Cytokine-Enriched NK Cell (m-ceNK) Platform in Solid Tumors   Business Wire
May 4, 2021
09:06AM EDT  ImmunityBio Reports 78% Complete Response Following Chemo-Free Combo Of IL-15 Superagonist Anktiva, Rituxan In Relapsed Non-Hodgkin Lymphoma Patients   Benzinga
09:00AM EDT  ImmunityBio Announces 78 Percent Complete Response Following Chemotherapy-Free Combination of IL-15 Superagonist Anktiva with Rituxan in Relapsed Non-Hodgkin Lymphoma Patients   Business Wire
May 3, 2021
06:16AM EDT  ImmunityBio, In Prospectus Supplement Dated April 30, Says May Offer And Sell Shares Having Offering Price Of Up To $500M   Benzinga
Apr 29, 2021
09:18AM EDT  ImmunityBio Launches Phase 2 Trial Of IL-15 Superagonist Anktiva With Antiretroviral Therapy To Inhibit HIV Reservoirs   RTTNews
09:11AM EDT  ImmunityBio Announces Launch Of Phase 2 Trial Of IL-15 Superagonist Anktiva With Antiretroviral Therapy To Inhibit HIV Reservoirs   Benzinga
Apr 22, 2021
09:17AM EDT  ImmunityBio Announces 100th Patient Dosed With Proprietary Natural Killer Cells; NK Trials Cover Multiple Indications   Benzinga
Apr 13, 2021
10:35AM EDT  ImmunityBio Shares Up ~7% Following National Health Institutes ClinicalTrials.gov Listing For Co.'s 'COVID-19 Supplemental Vaccine Boost to Enhance T Cell Protection in Those Who Have Already Received EUA S-Based Vaccines' As Recruiting   Benzinga
Apr 8, 2021
10:59AM EDT  Single Dose Of ImmunityBio's Dual Antigen COVID-19 Vaccine Induces Ten-Fold Increase In T-Cell Responses   Benzinga
09:13AM EDT  ImmunityBio Announces Single Prime HAd5 COVID-19 Vaccination Induces 10-Fold Increase In T Cell Response Equivalent   RTTNews
09:03AM EDT  ImmunityBio Announces Data Showing Its COVID-19 Vaccine Candidate Induced A 10-Fold Increase In T Cell Response Equivalent To T Cell Responses From Patients Previously Infected With SARS-CoV-2   Benzinga
09:00AM EDT  ImmunityBio Announces Single Prime hAd5 COVID-19 Vaccination Induces a 10-Fold Increase in T Cell Response Equivalent to T Cell Responses from Patients Previously Infected with SARS-CoV-2   Business Wire
Apr 7, 2021
01:32PM EDT  Watching ImmunityBio Shares; Traders Circulate Report 'Single Prime hAd5 Spike(S) + Nucleocapsid (N) Dual Antigen Vaccination of Healthy Volunteers Induces a Ten-Fold Increase in Mean S- and N- T-Cell Responses Equivalent to T-Cell Responses from...'   Benzinga
Apr 1, 2021
09:44AM EDT  ImmunityBio Appoints Linda Maxwell And CEO Richard Adcock To Board   RTTNews
09:36AM EDT  ImmunityBio Appoints Dr. Linda Maxwell and CEO Richard Adcock to Board of Directors   Business Wire
Mar 29, 2021
10:34AM EDT  ImmunityBio's Prostate Cancer Vaccine Shows Early Signs Of Clinical Activity, Durable Stable Disease   Benzinga
09:02AM EDT  ImmunityBio Announces 12-Month Overall Survival Probability Of 83% In NCI-Led Phase 1 Study Of Multi-Targeted hAd5 Immunotherapy Vaccine In Patients With Advanced Metastatic Prostate Cancer   Benzinga
Mar 22, 2021
09:10AM EDT  ImmunityBio Says NIH-Led Research Affirms PD-L1 T-haNK Therapy Overcomes T-Cell Escape In Multiple Types Of Resistant Tumors   Benzinga
09:00AM EDT  ImmunityBio Announces NIH-Led Research Affirming that PD-L1 T-haNK Therapy Overcomes T-Cell Escape in Multiple Types of Resistant Tumors   Business Wire
Mar 19, 2021
07:39AM EDT  ImmunityBio's COVID-19 Vaccine Will Be Manufactured In South Africa: Bloomberg   Benzinga
05:17AM EDT  ImmunityBio to Have Covid-19 Vaccine Made in South Africa   Benzinga
Mar 15, 2021
09:10AM EDT  ImmunityBio: Positive Interim Phase I Safety Data Of HAd5 T-Cell COVID-19 Vaccine Candidate In Oral, Sublingual Formula   RTTNews
09:00AM EDT  ImmunityBio Announces Positive Interim Phase I Safety Data of hAd5 T-Cell COVID-19 Vaccine Candidate in Oral and Sublingual Formulations   Business Wire
Mar 11, 2021
09:13AM EST  ImmunityBio : ACE2 Decoy COVID-19 Therapeutic Shows High Binding To SARS-CoV-2 Variants And Neutralizes Live Viruses   RTTNews
09:03AM EST  ImmunityBio Announces Development Of ACE2 Decoy COVID-19 Therapeutic   Benzinga
09:00AM EST  ImmunityBio Announces Novel ACE2 Decoy COVID-19 Therapeutic that Shows High Binding to SARS-CoV-2 Variants and Neutralizes Live Viruses   Business Wire
Mar 10, 2021
09:06AM EST  ImmunityBio Highlights Has Begun Trading On Nasdaq Following Merger With NantKwest, Trading On Ticker 'IBRX'   Benzinga
09:00AM EST  ImmunityBio Begins Trading Today on Nasdaq as Large Cap Biotechnology Company   Business Wire


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC